Strategies and hopes for dealing with resistance to serpatinib
Selpatinib is a powerful targeted drug for cancer patients with RET gene fusions or mutations. But over time, like many other anticancer drugs, some patients develop resistance to seputinib.
First of all, the emergence of drug resistance does not mean the end of treatment, but is a signal that treatment strategies need to be adjusted. When drug resistance occurs, patients should actively communicate with the medical expert team and conduct an in-depth comprehensive evaluation. This often involves re-sequencing the genes to see if the cancer cells have developed new genetic mutations or amplifications that may be the source of drug resistance.
Depending on the specific cause of drug resistance, the medical team will develop a targeted treatment plan. For example, if MET amplification is the main cause of resistance, then combined use of a MET inhibitor, such as capmatinib, may be an effective solution. This combination treatment approach has shown potential in combating drug resistance in actual clinical practice.
In addition, in addition to adjustment of drug therapy, other treatments, such as local radiation therapy or systemic chemotherapy, may also be considered based on the patient's specific condition and the doctor's guidance. At the same time, participating in clinical trials of new drugs may also bring new treatment opportunities to patients.
During the entire treatment process, the patient's psychological adjustment is also crucial. Patients may feel uneasy and worried when faced with the uncertainty that comes with drug resistance. However, maintaining a positive attitude and establishing a good communication mechanism with the medical team will be an important step in overcoming drug resistance and heading towards recovery.
To sum up, when resistance to seputinib occurs, through comprehensive evaluation, precise treatment adjustment, and a positive attitude of the patient, we are still expected to find a way to break through the resistance, thereby extending the patient's survival and improving their quality of life.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)